

22nd Annual Meeting of the Swiss Transplantation Society



January 23-24, 2025

Congress Hotel Seepark
Thun, Switzerland

Congress Organization

Prof. Philipp Dutkowski, President STS
Prof. Nicolas Müller & Dr. Alexander Ritter,
Chairs of the Scientific Committee

Congress Secretariat

Meeting.com Sàrl Congress Organisation
www.meetingcom.ch • info@meetingcom.ch

Online registration on www.meetingcom.ch/
Conferences & Meetings

Your partner in transplantation

**Every life line
tells a story**

Wedding
Birth of the children
Organ failure
Transplantation
Wedding of the children
Birth of the grandchildren

Date of preparation: 05/2019 TX_2019_0005_CH

Welcome letter

Dear Colleagues, Dear Friends,

It is with great pleasure that we invite you, on behalf of the Swiss Transplantation Society, to join us at the 22nd Annual Congress on January 23 and 24, 2025 at the Congress Hotel Seepark, in Thun.

For this annual meeting our scientific committee has prepared a very attractive program, covering timely topics and relevant issues, both for transplant patients and for transplant specialists.

To foster participation of our young colleagues and to motivate them pursuing a career in transplantation, the scientific committee has introduced a new format, the rapid fire session, where young investigator can showcase their research and compete for a new award dedicated to young academic colleagues. We are very thankful to our sponsors who made this possible. With 19 abstracts submitted, the start was highly successful!

One session is entirely dedicated to pediatrics – understanding the unique aspects of pediatric transplantation and the complexities involved in providing optimal care for these patients across various stages of life.

Many other timely topics will be addressed. - We would like to highlight three: **gender** is becoming an important topic at many levels. **Organ repair** is the new kid on the block, and we are happy to welcome Prof. Stefan Schneeberger from Innsbruck and Dr. Corinne Antoine from Paris, who will report about their pioneering work. We also won Prof. Camille Kotton, from Boston, one of the world-leaders in all aspects of **CMV**. She will report on new developments in this rapidly changing field.

Our program will end up with the ceremony of the STS Innovation awards 2024, and a final session on a special case to remember, presented by each center.

We would like to thank our sponsors for their very essential participation and of course our colleagues at meeting.com for their faithful, efficient and friendly support. The Board of our Society and the Scientific Committee are very much looking forward to seeing you soon in Thun and wish you all a very pleasant and fruitful congress.



Philipp Dutkowski
President STS



Nicolas Mueller
Chair, Scientific Committee 2025

General information/ Credits

Venue

Congress Hotel Seepark – Seestrasse 47, 3602 Thun – www.seepark.ch
T +41 (0)33 226 12 12 – info@seepark.ch

Congress Office

Office Secretariat STS – meeting-com Congress Organisation
Rue des Pâquis 1 – CP 100 – 1033 Cheseaux-sur-Lausanne
T +41 (0)21 312 92 61 – info@meetingcom.ch



The credits are in demand to the following societies

SGC/SSC

Schweizerische Gesellschaft für Chirurgie
Société Suisse de Chirurgie

SGI/SSI

Schweizerische Gesellschaft für Infektiologie
Société Suisse d'Infectiologie

SGG/SSG

Schweizerische Gesellschaft für Gastroenterologie
Société Suisse de Gastroentérologie

SSAI/SGAI

Schweizerische Gesellschaft für Allergologie und Immunologie
Société Suisse d'Allergologie et d'Immunologie

SGN/SSN

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie

SGHC/SSCC

Schweizerische Gesellschaft für Herz- und thorakale Gefässchirurgie
Société Suisse de Chirurgie Cardiaque et Vasculaire Thoracique

SSAPM

Schweizerische Gesellschaft für Anästhesiologie und Perioperative Medizin
Société Suisse d'Anesthésiologie et de Médecine Périopératoire

SGAIM/SSMIG

Schweizerische Gesellschaft für Allgemeine Innere Medizin
Société Suisse de Médecine Interne Générale

SGH/SSH

Schweizerische Gesellschaft für Hämatologie
Société Suisse d'Hématologie

SSP

Schweizerische Gesellschaft für Pneumologie
Société Suisse de Pneumologie

SGI/SSMI

Schweizerische Gesellschaft für Intensivmedizin
Société Suisse de Médecine Intensive

Awards for Young Clinicians or Investigators

This year, the Scientific Committee would like to give a voice to young fellows, by introducing for the first time oral and poster presentations of their submissions of work carried out during the year 2024.

The oral and poster presentations are dedicated to “young investigators” (medical doctors, nurses, allied health professionals). In order to be chosen as a presenter of a short report or poster, the first author must fulfill all of the following criteria:

- a maximum of 10 years of clinical experience from passing the final medical exams or master/PhD in nursing science
- first author is not the head of a research group;
- first author is not an established university lecturer (i.e., not “Privatdozent”, no *venia legendi*) or professor in nursing research.

The 10 highest scoring abstracts will be presented as oral presentations on Friday January 24, 2025. The additional submissions will have the possibility to present their work during a dedicated poster walk during the lunch break on the Friday as well.

The committee would like to reward the best oral presentation and the best poster with a prize of CHF 750.00 each, for a total of CHF 1,500.00.

These awards are kindly supported by



Abstract Book



https://www.meeting-com.ch/fileadmin/user_upload/Abstract_books/BOOK_OF_ABSTRACTS_STS_2025_all.pdf

Thursday, January 23, 2025

09.30 – 12.00	Swiss Transplant Working Group Meetings (to be registered separately)	
13.00 – 13.05	Welcome <i>Philipp Dutkowski, Basel</i> <i>President of the Swiss Transplantation Society</i>	Room Genève
13.05 – 13.25	Swiss Transplant Annual Activity Report <i>Franz Immer, Franziska Beyeler, Swiss Transplant, Bern</i>	
13.25 – 13.45	STCS Report <i>Michael Koller, Basel</i>	

13.45 – 14.30	Session 1	Room Genève
	SPONSORED SYMPOSIUM by OM Pharma Chair: Patrizia Amico, Basel	
13.45 – 14.30	Tailoring Immunosuppression: Integrating Immune Monitoring and Personalized Drug Management <i>Fadi Haidar, Geneva</i>	

14.30 – 16.00	Session 2	Room Genève
	COORDINATOR'S CORNER (program with SDTA) Chairs: Barbara Wildhaber, Geneva; Pascale Tinguely, Zurich	
14.30 – 15.10	Ice-free organ preservation – a new stage of transplantation technology <i>Gerald Brandacher, Innsbruck (AT)</i>	
15.10 – 15.15	Questions	
15.15 – 15.55	Machine Perfusion Programs in Liver Transplantation: A Process of Implementing Sustainable Innovative Change <i>Keziah Crick, London (UK)</i>	
15.55 – 16.00	Questions	

16.00 – 16.30	Coffee break – visit of the exhibition	Foyer 1st floor
----------------------	---	-----------------

Thursday, January 23, 2025

16.30 – 17.15	Session 3	Room Genève
	SPONSORED SYMPOSIUM BY MSD & Takeda CMV Management from prophylaxis to treatment Chair: Nicolas Müller, Zürich	 
16.30 – 17.00	Keynote Lecture <i>Camille Kotton, Boston (US)</i>	
17.00 – 17.15	Discussion	

17.15 – 18.15	Session 4	Room Genève
	STS AWARDS Oral presentation of the six highest ranking papers Chair: Patricia Hirt, Basel	 
	CLINICAL PAPERS	
17.15 – 17.25	Recipient-Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma-An ELTR Study <i>Christian Magyar, Bern</i>	
17.25 – 17.35	Surgical site infections after kidney transplantation are independently associated with graft-loss <i>Peter Schreiber, Zurich</i>	
17.35 – 17.45	Early complications in kidney donors and course of health-related quality of life 12 months after donation: An analysis of the Swiss Organ Living-Donor Health Registry <i>Charlotte Brügger, Basel</i>	
	LABORATORY PAPERS	
17.45 – 17.55	Selective haematological cancer eradication with preserved haematopoiesis <i>Simon Garaudé, Basel</i>	
17.55 – 18.05	Dietary or pharmacological inhibition of insulin-like growth factor-1 protects from renal ischemia-reperfusion injury in mice <i>Arnaud Lyon, Lausanne</i>	
18.05 – 18.15	Circulating factors, in both donor and ex-situ heart perfusion, correlate with heart recovery in a pig model of CDC <i>Selianne Graf, Bern</i>	

18.15 – 18.45	GENERAL ASSEMBLY	Room Genève
19.15	STS Awards	Lobby Hotel Seepark
19.30	Networking Dinner	Parksaal Hotel Seepark



Envarsus® vs. Prograf® und vs. Advagraf®³

- ➔ Signifikant niedrigere Gesamttagesdosis
- ➔ Verlängerte Zeit bis zum Peak (T_{max})
- ➔ Geringere Peak-to-Trough-Schwankungen
- ➔ Niedrigere Peak-Werte (C_{max})

Referenzen

¹ Fachinformation Envarsus®, www.swissmedinfo.ch. ² Langone A. et al. Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacrolimus (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015;29(9):796-805. ³ Tremblay S. et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. Am J Transplant. 2017;17(2):432-442.

Envarsus®: Tacrolimus-Monohydrat. **I:** Prophylaxe der Transplantatabstossung bei Erwachsenen Nieren- und Lebertransplantatempfängern. Behandlung der Transplantatabstossung, die sich gegenüber anderen Immunsuppressiva als therapieresistent erweist, bei erwachsenen Patienten. **D:** Tabletten sind einmal täglich zerlegt und sofort nach der Einnahme aus der Blisterpackung mit Flüssigkeit (Wasser) und auf nüchternen Magen einzunehmen. **Prophylaxe Nierentransplantatabstossung:** Start einer Therapie mit Envarsus innerhalb von 24 Stunden post-operativ mit 0,17 mg/kg/Tag, einmal täglich. **Prophylaxe Lebertransplantatabstossung:** Start einer Therapie mit Envarsus innerhalb von 24 Stunden post-operativ mit 0,11 – 0,13 mg/kg/Tag, einmal täglich. **Umstellung von Prograf® oder Advagraf® auf Envarsus:** Umstellung im Verhältnis 1:0,7 der täglichen Gesamtdosis (10% geringere Erhaltungsdosis unter Envarsus), einmal täglich. Die Blutkonzentration sollte nach einer Umstellung während zwei Wochen kontrolliert und Dosisanpassungen durchgeführt werden. **Umstellung von Ciclosporin auf Envarsus:** Aufgrund einer verlängerten Halbwertszeit von Ciclosporin unter Tacrolimus ist eine kombinierte Gabe nicht empfohlen. **Behandlung Transplantatabstossung nach Nieren- und Lebertransplantation:** Nach einer Umstellung von anderen Immunsuppressiva auf Envarsus, muss die Behandlung mit der jeweils in Nieren- und Lebertransplantation empfohlenen oralen Initialdosis für die Prophylaxe der Transplantatabstossung beginnen. **Ethnische Zugehörigkeit:** Patienten mit schwarzer Hautfarbe können höhere Tacrolimus-Dosen benötigen. Eine Umstellung von Prograf auf Envarsus findet daher mit einem Konversionsfaktor von 1,0,85 der täglichen Gesamtdosis statt. **Überwachung:** Talispiegel sollten ca. 24 Stunden nach der Gabe von Envarsus, unmittelbar vor der nächsten Dosis, erfolgen. **KF:** Überempfindlichkeit gegen

Tacrolimus oder Makrolide sowie einen der Hilfsstoffe. **VM:** Unter- oder Überexposition kann zur Transplantatabstossung oder anderen schwerwiegenden unerwünschten Wirkungen führen. Eine Anwendung bei Kindern unter 18 Jahren ist aufgrund der begrenzten Datenlage nicht empfohlen. Bei gleichzeitiger Anwendung von CYP3A4-Inhibitoren oder -Induktoren sollten Tacrolimus-Blutspiegel überwacht werden. Das Ansprechen auf Impfungen kann durch Immunsuppressiva beeinträchtigt sein. Die Anwendung von Lebendimpfstoffen sollte vermieden werden. Bei angeborener Glukose-Galaktose-Intoleranz, Laktase-Mangel oder Glukose-Galaktose-Malabsorption sollte auf die Einnahme von Envarsus verzichtet werden. **Gastrointestinale Perforationen, Augenerkrankungen, Kardiomyopathien, QT-Verlängerungen, EBV-lymphoproliferative Erkrankungen, opportunistische Infektionen, PNE-Syndrom, Erythroblastopenien** wurden beobachtet. **S/S:** Die Gabe von Tacrolimus an Schwangere kommt in Betracht, wenn keine sichere Alternative zur Verfügung steht und wenn das potenzielle Risiko für den Fötus durch den wahrgenommenen Nutzen einer solchen Behandlung gerechtfertigt ist. Auf das Stillen sollte während einer Einnahme von Envarsus verzichtet werden. **UAW:** Die häufigsten unerwünschten Wirkungen unter Tacrolimus (>10% der Patienten) sind: Infektionen, Tumoren, Erkrankungen des Blutsystems, allergische Reaktionen, Stoffwechselstörungen, psychiatrische Erkrankungen, Erkrankungen des Nervensystems, Augenerkrankungen, Erkrankungen des Ohrs, kardiovaskuläre Erkrankungen, Atemwegserkrankungen, gastrointestinale Erkrankungen, Leber- und Gallenerkrankungen, Hauterkrankungen, Erkrankungen der Skelettmuskulatur, Nieren- und Harnwegserkrankungen, Fieber, Schmerzen und Beschwerden, asthenische Zustände, Ödeme, gestörtes Empfinden der Körpertemperatur, erhöhte Blutspiegel der alkalischen Phosphatase, Gewichtszunahme, primäre Funktionsstörung des Transplantats. **IA:** Die gleichzeitige Anwendung von CYP3A4-Hemmern oder -Induktoren kann die Blutwerte von Tacrolimus erhöhen oder senken. Wechselwirkungen mit Arzneimitteln, welche ebenfalls an Plasmaproteine binden, sind zu berücksichtigen. Bei Anwendung von Arzneimitteln, die ebenfalls nephro- und neurotoxisch wirken, ist Vorsicht geboten. Eine hohe Kaliumzufuhr oder die Verwendung kaliumsparender Diuretika ist zu vermeiden. **P:** Envarsus® 0,75mg, 1 mg, 4mg zu je 30 Retardtabletten. Abgabekategorie A. Detaillierte Informationen: www.swissmedinfo.ch. Zulassungsinhaber: Chiesi SA, CH-1752 Villars-sur-Glane. Vertrieb: OM Pharma Suisse AG, CH-1752 Villars-sur-Glane. Stand: Juli 2023. **Referenzen auf Anfrage erhältlich.**

CH-EW-24020/202501

Friday, January 24, 2025

08.30 – 09.00

Keynote Lecture

Chair: Vanessa Banz, Bern

Room Genève

08.30 – 09.00

Does gender play a role in transplantation?

Sex and Gender Inequalities in Transplant Medicine

Berna Özdemir, Bern

09.00 – 10.10

Session 5

Rapid Fire Session

Chair: Jean Villard, Geneva

Room Genève

09.00 – 09.06
S01

Comparative Analysis of Listing Criteria for Hepatocellular Carcinoma: Milan Criteria Versus Ontario Criteria - a Unos Analysis

Christian Magyar, Bern

09.07 – 09.13
S02

Immune Profiling before and early after Kidney Transplantation Identifies SCF as a Potential Biomarker of Long-Term Allograft Outcome

Louis Stavart, Lausanne

09.14 – 09.20
S03

Biopsy-Based Transcriptomics allow Early Detection of Rejection, Gradual Rejection Phenotyping, and Monitoring of Anti-Rejection Treatment Responses through Follow-Up Biopsies

Lukas Weidmann, Zurich

09.21 – 09.27
S04

Effect of Felzartamab Anti-CD38 Treatment on the Molecular Phenotype of Antibody-Mediated Rejection in Kidney Transplant Biopsies

Matthias Diebold, Basel

09.28 – 09.34
S05

Bicentric Validation of the Diffusion-Weighted Magnetic Resonance Imaging as a Noninvasive Tool to Assess Fibrosis Level for Allograft and Native Kidneys

Aurélien Huber, Geneva

09.35 – 09.41
S06

The Burden of Abo Incompatible Kidney Transplantation: Readmission Rates and Complications, a Twenty-Year Analysis

Caroline Berchtold, Basel

09.42 – 09.48
S07

Impact of Emergency Lung Transplantation Insights from the Edge

Konstantina Spetsotaki, Zurich

09.49 – 09.55
S08

Case-Report of a Successful Living Donor Kidney Transplantation in a Child with Bilateral Kidney Agenesis

Julien Caccia, Bern

09.56 – 10.02
S09

Incidence and Risk Factors of Cytomegalovirus Drug Resistance Mutations in Solid Organ Transplant Recipients at the University Hospital Of Zurich

Britta Hirsch, Zurich

10.03 – 10.09
S10

Social Media Call to search for an Altruistic Kidney Donor: ethical or not?

Nathalie Hammer, Bern

Friday, January 24, 2025

10.10 – 10.45 **Coffee break – visit of the exhibition** Foyer 1st floor

10.45 – 11.40 **SPONSORED SYMPOSIUM BY ASTELLAS** Room Genève

Organ Recovery and Repair Future Perspectives

Chair: Thomas Müller, Zurich;
Philipp Dutkowski, Basel



10.45 – 11.05 **The new Era of Organ Preservation: Quality Times for Organs**
Stefan Schneeberger, Innsbruck (AT)

11.05 – 11.25 **Implementation of organ ex-situ perfusion protocol in France: Methodology and results**
Corinne Antoine, Paris (FR)

11.25 – 11.40 **Discussion**

11.40 – 12.35 ROOM Genève

Session 6

Paediatric Session

Chair: Massimiliano Bertacchi, Geneva; Giuseppina Spartà, Zurich

11.40 – 11.55 **Clinical Aspects of Pediatric Heart Allocation**
Vanessa Sitte, Zurich; Sonja Budäus, Zurich

11.55 – 12.10 **Infectious Diseases in the First Year After Solid Organ Transplantation in Children in the Swiss Transplant Cohort Study**
Nathalie Rock, Geneva

12.10 – 12.25 **PLUTO, A Multicenter Clinical Trials to Optimize Perioperative Care for Children Receiving Kidney Transplants**
Wesley Hayes, Zurich

12.25 – 12.35 **Discussion**

12.35 – 13.45 **Lunch break – visit of the exhibition** Foyer 1st floor

13.00 – 13.30 **Poster walk**

13.45 – 14.15 **STS EXCELLENCE & INNOVATION AWARDS 2024** ROOM Genève

with the kind support of Astellas
Chair: Markus Barten, Hamburg (DE)



13.45 – 13.55 **Welcome word**

13.55 – 14.05 **STS Excellence Award**

14.05 – 14.15 **STS Innovation Award**

Friday, January 24, 2025

14.15 – 14.30 **Best Oral & Best Poster presentation Awards** ROOM Genève

with the kind support of Astellas



14.15 – 14.30 **Awards**
Nicolas Müller, Zurich

14.30 – 16.00 ROOM Genève

Session 7

A case to remember

Chair: Alexander Ritter, St. Gallen

14.30 – 14.45 **Hematopoietic cell transplantation – cure for hematopoietic neoplasm after liver transplantation?**
Beatrice Drexler, Basel

14.45 – 15.00 **Lung transplantation**
Pieter-Jan Gijls, Lausanne

15.00 – 15.15 **Heart transplantation**
David Reineke, Bern

15.15 – 15.30 **Pancreas / Islet transplantation**
Fadi Haidar, Geneva

15.30 – 15.45 **Liver transplantation**
Pascale Tinguely, Zurich

15.45 – 16.00 **Kidney transplantation**
Christian Kuhn, St. Gallen

16.00 **Closing remarks** ROOM Genève

Philipp Dutkowski, Basel – President of the Swiss Transplantation Society



Transplant Fellows Course: Core Curriculum



23rd Annual Meeting of the Swiss Transplantation Society



SAVE THE DATE

Friday, 9th May 2025

Auditoire Paternot, AGORA (CHUV, Lausanne)
Fondation ISREC, Rue du Bugnon 25A, 1005 Lausanne

Online registration on
www.meeting-com.ch
Conferences & Meetings



Language: English

Organizing committee

Dr Isabelle Binet
PD Dr Angela Koutsokera
Prof Nicolas Müller
Prof Jean Villard

Congress Secretariat

Meeting-com Sàrl Congress Organisation
www.meetingcom.ch • info@meetingcom.ch



January 22-23, 2026

Congress Hotel Seepark
Thun, Switzerland

Congress Secretariat

Meeting-com Sàrl Congress Organisation
www.meeting-com.ch • info@meeting-com.ch

SAVE THE DATE

Committees

STS Board

Prof. Philipp Dutkowski, Basel	President
Prof. Jean Villard, Geneva	President-elect
Dr Alexander Ritter, St. Gallen	Secretary
PD Dr Patrizia Amico, Basel	Treasurer
Prof. Nicolas Müller, Zurich	Science and Research
Dr Angela Koutsokera, Lausanne	Education/CME
Dr Federico Storni, Bern	Communication/Website
Prof. Hendrik Tevæarai Stahel, Zurich	Past President

STS Scientific Committee Members

Amico Patrizia, Basel	Immunology & Kidney	Internal Medicine
Banz Vanessa, Bern	Liver	Internal Medicine
Duchosal Michel, Lausanne	Bone marrow	Internal Medicine
Dutkowski Philipp, Zurich	Liver	Surgery
Ferrari-Lacraz Sylvie, Geneva	Immunology	Internal Medicine
Flammer Andreas, Zurich	Heart	Internal Medicine
Folie Patrick, St.Gallen	Kidney	Surgery
Golshayan Déla, Lausanne	Kidney	Internal Medicine
Haidar Fadi, Geneva	Kidney	Internal Medicine
Hirt-Minkowski Patricia, Basel	Kidney	Internal Medicine
Kremer Andreas, Zurich	Liver	Internal Medicine
Longnus Sarah, Bern	Heart	Basic Science
Müller Nicolas, Zurich	Infectious diseases	Internal Medicine
Neofytos Dionysios, Geneva	Infectious diseases	Internal Medicine
Schuurmans Macé, Zurich	Lung	Thoracic Surgery

Liver Assist

Unlock the power of Flexibility

With more than 25 years of experience in liver perfusion, XVIVO is an expert in the field of optimized preservation and evaluation of donor livers.

XVIVO Liver Assist has been clinically proven to:

- Enable assessment of donor livers under Hypothermic and Normothermic conditions ^{1,2}

¹ Otto B. van Leeuwen et al. "Sequential hypothermic and normothermic machine perfusion enables safe transplantation of high-risk donor livers" AJT 2022

² Janina Eden et al. "Assessment of liver graft quality during hypothermic oxygenated perfusion: the first international validation study" JHEP 2024

- It allows for safe preservation up to 24 hours avoiding the need for nighttime surgery ³

³ Isabel Brügggenwirth et al. "Prolonged hypothermic machine perfusion enables daytime liver transplantation – an IDEAL stage 2 prospective clinical trial." E.ClinicalMedicine 2024

- Be cost effective due to reduction of post-Transplant complications ⁴

³ Endo, C et al. "Cost-effectiveness of Dual Hypothermic Oxygenated Machine Perfusion Versus Static Cold Storage in DCD Liver Transplantation" Transplantation 2024



Sponsors

PLATINUM



GOLD



SPONSORS

